Try Mental Wellness – Lifestyle
Author:
Aptevo Therapeutics
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
Aptevo Provides State of the Business Report and 2025 Financial Results
March 26, 2026
Aptevo to Participate in March 2026 Conferences
March 19, 2026